Free Trial

Compugen (CGEN) Competitors

Compugen logo
$1.53 -0.01 (-0.65%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.56 +0.02 (+1.63%)
As of 07/25/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CGEN vs. ORKA, ARVN, RAPP, ATYR, OPT, PGEN, SLDB, TERN, TRML, and PRTC

Should you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Oruka Therapeutics (ORKA), Arvinas (ARVN), Rapport Therapeutics (RAPP), aTyr Pharma (ATYR), Opthea (OPT), Precigen (PGEN), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

Compugen vs. Its Competitors

Compugen (NASDAQ:CGEN) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Compugen has higher revenue and earnings than Oruka Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$27.59M4.95-$14.23M-$0.16-9.56
Oruka TherapeuticsN/AN/A-$83.72M-$4.51-3.16

Compugen has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.

Compugen presently has a consensus target price of $4.00, indicating a potential upside of 161.44%. Oruka Therapeutics has a consensus target price of $40.38, indicating a potential upside of 183.33%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Compugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oruka Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Oruka Therapeutics has a net margin of 0.00% compared to Compugen's net margin of -51.27%. Compugen's return on equity of -24.51% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen-51.27% -24.51% -12.19%
Oruka Therapeutics N/A -25.66%-23.39%

12.2% of Compugen shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 7 more articles in the media than Compugen. MarketBeat recorded 10 mentions for Oruka Therapeutics and 3 mentions for Compugen. Compugen's average media sentiment score of 0.63 beat Oruka Therapeutics' score of 0.45 indicating that Compugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
0 Very Positive mention(s)
5 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Oruka Therapeutics beats Compugen on 9 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGEN vs. The Competition

MetricCompugenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$137.43M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-9.5621.1828.1020.05
Price / Sales4.95288.62432.4890.19
Price / CashN/A42.7636.2258.56
Price / Book2.478.378.665.87
Net Income-$14.23M-$55.19M$3.25B$258.55M
7 Day Performance-0.65%5.88%4.22%3.73%
1 Month Performance-6.13%17.33%10.51%11.75%
1 Year Performance-13.56%4.42%34.40%18.03%

Compugen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGEN
Compugen
1.4458 of 5 stars
$1.53
-0.6%
$4.00
+161.4%
-13.1%$137.43M$27.59M-9.5670
ORKA
Oruka Therapeutics
2.7217 of 5 stars
$13.77
-5.3%
$40.38
+193.2%
N/A$544.39MN/A-3.05N/AUpcoming Earnings
Analyst Forecast
ARVN
Arvinas
4.031 of 5 stars
$7.52
+2.3%
$20.29
+169.8%
-73.4%$536.49M$263.40M-11.39420News Coverage
Upcoming Earnings
RAPP
Rapport Therapeutics
1.5043 of 5 stars
$14.39
-2.0%
$28.00
+94.6%
-27.7%$535.79MN/A-4.17N/ANews Coverage
ATYR
aTyr Pharma
2.1761 of 5 stars
$5.71
-4.7%
$20.20
+253.8%
+161.4%$533.14M$230K-7.0553News Coverage
Gap Up
High Trading Volume
OPT
Opthea
0.3847 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+55.0%$524.84M$120K0.008News Coverage
Gap Up
PGEN
Precigen
3.8544 of 5 stars
$1.83
+4.0%
$6.00
+227.9%
-5.4%$519.52M$3.92M-3.27190Positive News
SLDB
Solid Biosciences
3.0988 of 5 stars
$6.37
-0.3%
$15.10
+137.0%
-22.7%$495.32M$8.09M-2.13100High Trading Volume
TERN
Terns Pharmaceuticals
3.9798 of 5 stars
$5.64
flat
$15.63
+177.0%
-31.2%$492.58MN/A-5.1740
TRML
Tourmaline Bio
1.7459 of 5 stars
$18.23
-1.4%
$49.33
+170.6%
+15.5%$474.67MN/A-5.6844News Coverage
PRTC
PureTech Health
2.7886 of 5 stars
$18.56
+0.3%
$45.00
+142.4%
-14.4%$472.52M$4.83M0.00100Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:CGEN) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners